Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

63 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Diagnosis of Primary Ciliary Dyskinesia. An Official American Thoracic Society Clinical Practice Guideline.
Shapiro AJ, Davis SD, Polineni D, Manion M, Rosenfeld M, Dell SD, Chilvers MA, Ferkol TW, Zariwala MA, Sagel SD, Josephson M, Morgan L, Yilmaz O, Olivier KN, Milla C, Pittman JE, Daniels MLA, Jones MH, Janahi IA, Ware SM, Daniel SJ, Cooper ML, Nogee LM, Anton B, Eastvold T, Ehrne L, Guadagno E, Knowles MR, Leigh MW, Lavergne V; American Thoracic Society Assembly on Pediatrics. Shapiro AJ, et al. Among authors: chilvers ma. Am J Respir Crit Care Med. 2018 Jun 15;197(12):e24-e39. doi: 10.1164/rccm.201805-0819ST. Am J Respir Crit Care Med. 2018. PMID: 29905515 Free PMC article.
Diagnostic testing of patients suspected of primary ciliary dyskinesia.
Stannard WA, Chilvers MA, Rutman AR, Williams CD, O'Callaghan C. Stannard WA, et al. Among authors: chilvers ma. Am J Respir Crit Care Med. 2010 Feb 15;181(4):307-14. doi: 10.1164/rccm.200903-0459OC. Epub 2009 Nov 12. Am J Respir Crit Care Med. 2010. PMID: 19910612
Diagnosing primary ciliary dyskinesia.
O'Callaghan C, Chilvers M, Hogg C, Bush A, Lucas J. O'Callaghan C, et al. Thorax. 2007 Aug;62(8):656-7. doi: 10.1136/thx.2007.083147. Thorax. 2007. PMID: 17687094 Free PMC article.
Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.
Davies JC, Wainwright CE, Canny GJ, Chilvers MA, Howenstine MS, Munck A, Mainz JG, Rodriguez S, Li H, Yen K, Ordoñez CL, Ahrens R; VX08-770-103 (ENVISION) Study Group. Davies JC, et al. Among authors: chilvers ma. Am J Respir Crit Care Med. 2013 Jun 1;187(11):1219-25. doi: 10.1164/rccm.201301-0153OC. Am J Respir Crit Care Med. 2013. PMID: 23590265 Free PMC article. Clinical Trial.
An open-label extension study of ivacaftor in children with CF and a CFTR gating mutation initiating treatment at age 2-5 years (KLIMB).
Rosenfeld M, Cunningham S, Harris WT, Lapey A, Regelmann WE, Sawicki GS, Southern KW, Chilvers M, Higgins M, Tian S, Cooke J, Davies JC; KLIMB study group. Rosenfeld M, et al. J Cyst Fibros. 2019 Nov;18(6):838-843. doi: 10.1016/j.jcf.2019.03.009. Epub 2019 Apr 30. J Cyst Fibros. 2019. PMID: 31053538 Free PMC article. Clinical Trial.
A phase 3 study of tezacaftor in combination with ivacaftor in children aged 6 through 11 years with cystic fibrosis.
Walker S, Flume P, McNamara J, Solomon M, Chilvers M, Chmiel J, Harris RS, Haseltine E, Stiles D, Li C, Ahluwalia N, Zhou H, Owen CA, Sawicki G; VX15-661-113 Investigator Group. Walker S, et al. J Cyst Fibros. 2019 Sep;18(5):708-713. doi: 10.1016/j.jcf.2019.06.009. Epub 2019 Jun 26. J Cyst Fibros. 2019. PMID: 31253540 Free article. Clinical Trial.
63 results